Nowadays neurodegenerative diseases such as Alzheimer’s disease and Parkinson disease represent a worldwide health threat. Rasagiline is one well-known medication for the treatment of Parkinson's disease, but more and cheaper alternatives are required.1 For this reason, our group is currently investigating a new catalytic asymmetric arylating2 cyclization route - borylation-arylation-amination (BorArAm) (Scheme...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||